|
HRP20000904A2
(en)
*
|
1998-07-06 |
2001-12-31 |
Janssen Pharmaceutica Nv |
Farnesyl protein transferase inhibitors for treating arthropathies
|
|
PT1094839E
(pt)
*
|
1998-07-06 |
2003-09-30 |
Janssen Pharmaceutica Nv |
Inibidores da proteina farnesil transferase com propriedades de radiossensibilizacao (in vivo)
|
|
US6423519B1
(en)
*
|
1998-07-15 |
2002-07-23 |
Gpc Biotech Inc. |
Compositions and methods for inhibiting fungal growth
|
|
US6156746A
(en)
*
|
1998-08-25 |
2000-12-05 |
Bristol-Myers Squibb Company |
1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents
|
|
US6316436B1
(en)
|
1998-12-08 |
2001-11-13 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
AU2477400A
(en)
|
1998-12-08 |
2000-06-26 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
CA2377254C
(en)
*
|
1999-06-18 |
2009-08-18 |
Thyreos Corporation |
Non-malignant disease treatment with ras antagonists
|
|
US20020115696A1
(en)
|
1999-06-18 |
2002-08-22 |
Yoel Kloog |
Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
|
|
KR20030026069A
(ko)
*
|
2001-09-24 |
2003-03-31 |
주식회사 엘지생명과학 |
티엔에프계 단백질과 플라보피리돌의 조합에 의한 암세포특이적인 세포사멸 유도용 조성물
|
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
|
MX2007016175A
(es)
*
|
2005-06-14 |
2008-03-07 |
Schering Corp |
Inhibidor de aspartil proteasas.
|
|
TWI387592B
(zh)
|
2005-08-30 |
2013-03-01 |
Novartis Ag |
經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
|
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
JP5328640B2
(ja)
|
2006-04-19 |
2013-10-30 |
ノバルティス アーゲー |
６−ｏ−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにｃｓｆ−１ｒシグナル伝達を阻害する方法
|
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
EP3536690A1
(en)
|
2007-01-10 |
2019-09-11 |
MSD Italia S.r.l. |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
|
EA019951B1
(ru)
|
2007-03-01 |
2014-07-30 |
Новартис Аг |
Ингибиторы киназы pim и способы их применения
|
|
US8293769B2
(en)
|
2007-05-21 |
2012-10-23 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
|
EP2170076B1
(en)
|
2007-06-27 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
US8232402B2
(en)
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
|
JP2012508768A
(ja)
|
2008-11-13 |
2012-04-12 |
リンク・メディスン・コーポレーション |
アザキノリノン誘導体及びその使用
|
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
|
WO2010124531A1
(zh)
|
2009-04-30 |
2010-11-04 |
石药集团中奇制药技术（石家庄）有限公司 |
一种厄他培南中间体、含其的组合物及其制备方法
|
|
EP2440058A4
(en)
|
2009-06-12 |
2012-11-21 |
Dana Farber Cancer Inst Inc |
MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
|
|
WO2011046771A1
(en)
|
2009-10-14 |
2011-04-21 |
Schering Corporation |
SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
|
|
AU2010343102B2
(en)
|
2009-12-29 |
2016-03-24 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
|
MX2012010617A
(es)
|
2010-03-16 |
2012-10-05 |
Dana Farber Cancer Inst Inc |
Compuestos de imidazol y sus usos.
|
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
|
AU2011285909B2
(en)
|
2010-08-02 |
2016-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
|
EP4079856A1
(en)
|
2010-08-17 |
2022-10-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
|
WO2012145471A1
(en)
|
2011-04-21 |
2012-10-26 |
Merck Sharp & Dohme Corp. |
Insulin-like growth factor-1 receptor inhibitors
|
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
JP6106685B2
(ja)
|
2011-11-17 |
2017-04-05 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
|
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
AU2013323508B2
(en)
|
2012-09-28 |
2017-11-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are ERK inhibitors
|
|
US10112927B2
(en)
|
2012-10-18 |
2018-10-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
EP2925888B1
(en)
|
2012-11-28 |
2017-10-25 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3057956B1
(en)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
EP3057955B1
(en)
|
2013-10-18 |
2018-04-11 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
|
CA2972239A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
CN107427521B
(zh)
|
2015-03-27 |
2021-08-03 |
达纳-法伯癌症研究所股份有限公司 |
细胞周期蛋白依赖性激酶的抑制剂
|
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
EP4019515A1
(en)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
|
EP3525785B1
(en)
|
2016-10-12 |
2025-08-27 |
Merck Sharp & Dohme LLC |
Kdm5 inhibitors
|
|
IL315837A
(en)
|
2017-04-13 |
2024-11-01 |
Sairopa B V |
Anti-SIRP-alpha antibodies
|
|
US11098059B2
(en)
|
2017-11-08 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
JP7590185B2
(ja)
|
2018-06-25 |
2024-11-26 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
|
|
WO2020033288A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
EP3833668B1
(en)
|
2018-08-07 |
2025-03-19 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
EP3902542A4
(en)
|
2018-12-28 |
2022-09-07 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 and uses thereof
|
|
WO2021126729A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
WO2024182271A1
(en)
*
|
2023-02-27 |
2024-09-06 |
Enanta Pharmaceuticals, Inc. |
Fused heterotetracyclic antiviral agents
|
|
WO2024180169A1
(en)
|
2023-03-02 |
2024-09-06 |
Carcimun Biotech Gmbh |
Means and methods for diagnosing cancer and/or an acute inflammatory disease
|